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WHAT THIS PAPER ADDS?
 It has been reported that cilostazol reduces restenosis and repeated revascularization in patients with femoropopliteal lesions after
endovascular therapy. However, the effect in the case of an infrapopliteal lesion after balloon angioplasty remains unclear. This
study investigates the efﬁcacy of cilostazol after balloon angioplasty in critical limb ischemia patients with infrapopliteal lesions.a r t i c l e i n f o
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Objective: To investigate whether cilostazol reduces restenosis and revascularization after infrapopliteal
angioplasty. Design: This study was a retrospective analysis of a multicenter prospective registry.
Materials and methods: Between February and April 2011, 63 patients (68 limbs, 101 lesions) with critical
limb ischemia (CLI) were enrolled. Of these, 32 were cilostazol treated and 31 were the non-cilostazol-
treated group. Outcome measures were binary restenosis by angiogram, reocclusion, target lesion
revascularization (TLR), limb salvage rate and complete wound healing at 3 months.
Result: Procedural success was obtained in all patients. The backgrounds and lesion characteristics of
patients with isolated tibial artery disease and CLI did not differ signiﬁcantly between the two groups. In
a lesion-based analysis, binary restenosis and reocclusion were signiﬁcantly lower in the cilostazol group
than in the non-cilostazol group (56.8% vs. 86.0%; p ¼ 0.015, 20.5% vs. 43.6%; p ¼ 0.015, respectively). The
TLR was also signiﬁcantly lower in the cilostazol group (27.5% vs. 52.8%, p ¼ 0.014). After adjustment for
covariables, cilostazol was found to be associated with reduced angiographic restenosis, reocclusion and
TLR rates in CLI patients at 3 months after infrapopliteal angioplasty. However, it remained unclear
whether cilostazol was also associated with improved clinical outcomes.
Conclusion: Cilostazol may be associated with reduced restenosis, reocclusion and clinically driven TLR at
3 months after infrapopliteal angioplasty.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Endovascular therapy (EVT) is an effective and widely per-
formed treatment for patients with critical limb ischemia (CLI).1e3ardiology, Kokura Memorial
001, Japan. Tel.: þ81 93 511
ciety for Vascular Surgery. PublisheHowever, restenosis develops at high rates after EVT for infrapo-
pliteal lesions and this is still a major limitation.4 The success of
stent treatment has also been reported,5,6 but this technique is
effective only for very limited local lesions. No such efﬁcacy has
been established for long occlusions or pedal vessel lesions.
Treatment with a drug-coated balloon is also promising,7 but it is
currently not appropriate to use a drug-eluting balloon for all
infrapopliteal lesions for economic reasons.
There is also no consensus on the optimal therapy for patients
with CLI after EVT.8 Aspirin is usually prescribed. However,d by Elsevier Ltd. All rights reserved.
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claudicant patients with femoropopliteal artery lesions after EVT9,10
and might be effective for limb salvage after EVT in CLI patients
with infrapopliteal lesions.11 Cilostazol has multiple actions,
including vasodilation and improvement of the vascular endothe-
lium and microcirculation,12 in addition to antiplatelet activity. To
date, it is unclear whether the cilostazol inhibition of restenosis
observed for femoropopliteal lesions will also contribute to limb
salvage in patients with infrapopliteal lesions. Furthermore, in the
coronary ﬁeld, the peak of restenosis after balloon angioplasty
occurs at 3months, whereas this is observed at 6months after stent
placement.13,14 Therefore, we performed a retrospective analysis of
a prospective study to examine whether cilostazol inhibits reste-
nosis in de-novo infrapopliteal lesions based on angiography per-
formed 3 months after balloon angioplasty.
Methods
Research design
The study was performed as a retrospective analysis of a multi-
center prospective nonrandomized clinical registry to evaluate
angiographic restenosis after EVT. The efﬁcacy of cilostazol in pre-
venting angiographic restenosis after balloon angioplasty for
infrapopliteal disease was evaluated for 3 months. Patients with CLI
who had de-novo infrapopliteal disease without an inﬂow lesion
were enrolled in the study prior to EVT. Other inclusion criteria
were age 40 years old and a stenosis of >75% of the native vessel
diameter by visual estimate on angiography. Patients with previous
lower extremity bypass surgery, previous EVT, an inﬂow lesion
(ipsilateral aortoiliac and/or femoropopliteal), acute onset limb
ischemia, symptomatic heart failure, severe valvular heart disease,
dementia, or claudicant patients classiﬁed into Rutherford Category
1, 2 or 3 were excluded.
The study protocol was developed in accordance with the
Declaration of Helsinki. This study was registered in the University
Hospital Medical Information Network Clinical Trial Registry
(UMIN-CTR), which was approved by the International Committee
of Medical Journal Editors (No. UMIN000006488, J-BEAT Angio
registry: Japanese BElow-the-knee Artery Treatment for the
Angiographic assessment registry). All patients gave written
informed consent prior to revascularization.
Endovascular procedure and follow-up
After admission, the femoral, popliteal, dorsalis pedis and
posterior tibial arteries were palpated, and the extent of tissue loss
was recorded as part of the preoperative vascular study. The
anatomical indication was judged by digital subtraction angiog-
raphy and a lesion with >75% stenosis was treated. Selection of an
EVT approach was left to the discretion of the operator. Angioplasty
was performed with a crossover approach or an antegrade ipsilat-
eral approach using a 3 to 5 French sheath. After placing the sheath,
unfractionated heparin (5000 units) was routinely injected into the
artery. A 0.014-inch guide wire was advanced into the lesion and
a balloon catheter of optimal size was introduced. The appropriate
balloon length and diameter were determined by visual assess-
ment. Balloon inﬂation with nominal pressure was maintained for
at least 120 s. Aspirin (81e100 mg/day) was generally prescribed at
least 1 week prior to EVT. Clopidogrel (75 mg/day), ticlopidine
(100 mg twice a day) or cilostazol (100 mg twice a day) was added
at the discretion of the operator or according to the institutional
regimen before or after EVT. Patients were contacted at 1, 2 and 3
months after the procedure. At these times, evaluation of restenosis
was performed using duplex ultrasound. Bleeding events,myocardial infarction, stroke, repeat revascularization and leg
amputation were recorded. Follow-up angiography was scheduled
at 3 months. Patients with open ulcers were followed by a plastic
surgeon, who carefully assessed the severity of wounds, especially
those with infection, and determined the indication for antibiotic
therapy and amputation timing.
Deﬁnitions
Ischemic tissue loss was deﬁned as tissue loss associated with
ankle pressure<50mmHg or toe pressure<30mmHg.When these
measurements could not be obtained due to intractable resting
pain or a non-compressible artery because of severe calciﬁcation,
skin perfusion pressure (SPP) was measured on the dorsal and
plantar sides of the foot. SPP <40 mmHg was taken to indicate an
ischemic cause of tissue loss.15 Procedural success was deﬁned as
obtaining one straight-line ﬂow to the ulcer or gangrene region
without occurrence of ﬂow-limiting dissection. EVT with angio-
plasty was considered hemodynamically successful when post-
procedural SPP increased to >40 mmHg. Binary restenosis was
deﬁned as>50% stenosis on follow-up angiography. Reintervention
included repeat angioplasty or a bypass graft procedure. Limb
salvage was deﬁned as avoidance of above-the-ankle amputation.
Coronary artery disease was deﬁned as a history of revasculariza-
tion of the coronary arteries. Cerebrovascular disease was deﬁned
as a history of stroke and/or cerebral hemorrhage. Anemia was
regarded as a hemoglobin level <10 g/dl. Heart failure was deﬁned
as a patient with a previous diagnosis, a history of hospitalization,
or undergoing current treatment for heart failure. Diabetes was
deﬁned as HbA1c >6.5%, casual plasma glucose >200 mg/dl, or
treatment with oral hypoglycemic agents or insulin injection.
Hypertension was deﬁned as systolic blood pressure 140 mmHg
or diastolic blood pressure 90 mmHg, or ongoing therapy for
hypertension.
Outcome measures
The primary outcome measure was binary restenosis on an
angiogram at 3 months. Secondary outcome measures were reoc-
clusion and clinically driven target lesion revascularization (TLR).
Statistical analysis
Continuous variables are expressed as medians with inter-
quartile ranges and were compared by ManneWhitney U-test.
Categorical variables were compared by chi-square test or Fisher’s
exact test. Clinical efﬁcacy of cilostazol was analyzed using a logistic
regression model. To correct for potential confounders, the results
were adjusted for age, gender, hyperlipidemia, aspirin and statins.
P < 0.05 was considered to be signiﬁcant.
Results
Baseline characteristics
Between February and April 2011, a total of 73 patients (83
limbs) were found to be eligible for the study, of whom 10 patients
(15 limbs) were subsequently excluded because of refusal of
consent. Therefore, 63 patients (68 limbs, 101 lesions) were
enrolled (Fig. 1). Patients were treated with (n ¼ 32) or without
(n ¼ 31) cilostazol. Six different antiplatelet therapies were
administered: aspirin alone (n ¼ 14), thienopyridines alone (n ¼ 2),
cilostazol alone (n ¼ 3), aspirin þ thienopyridines (n ¼ 15),
aspirin þ cilostazol (n ¼ 16), thienopyridines þ cilostazol (n ¼ 3),
Table 2
Patient characteristics.
Variable Cilostazol (þ) Cilostazol () P value
Number of patients 32 31
Age (IQR), yrs 71 (66e82) 76 (71e81) 0.31
Female gender (%) 12 (37.5) 15 (48.4) 0.38
BMI (IQR), kg/m2 22.3 (20.3e23.7) 21.2 (19.3e24.2) 0.49
Ambulatory (%) 18 (58.1) 12 (46.2) 0.37
Hypertension (%) 27 (84.4) 23 (74.2) 0.32
Hyperlipidemia (%) 16 (50.0) 10 (32.3) 0.15
Diabetes (%) 20 (62.5) 12 (61.3) 0.92
HbA1c (IQR), % 6.4 (5.3e6.9) 6.0 (5.1e6.5) 0.31
Hemodialysis (%) 17 (53.1) 19 (61.3) 0.51
Smoking
Previous (%) 22 (68.8) 25 (80.6) 0.28
Current (%) 10 (31.3) 6 (19.4) 0.28
Anemia (%) 8 (25.0) 10 (32.3) 0.52
Heart failure (%) 22 (68.8) 23 (74.2) 0.63
Coronary artery disease (%) 14 (43.8) 13 (41.9) 0.88
Cerebrovascular disease (%) 5 (15.6) 7 (22.6) 0.48
Serum albumin (IQR), g/dl 3.6 (3.3e3.8) 3.5 (3.0e3.9) 0.71
C-reactive protein (IQR), mg/dl 0.5 (0.2e2.2) 0.4 (0.1e2.8) 0.86
Medication
Aspirin (%) 26 (81.3) 29 (93.5) 0.14
Thienopyridine (%) 13 (40.6) 17 (54.8) 0.26
Warfarin (%) 5 (15.6) 6 (19.4) 0.70
Statins (%) 11 (34.4) 6 (19.4) 0.18
Number of Limbs 34 34
Preprocedural ABI (IQR) 0.73 (0.63e0.87) 0.72 (0.63e0.80) 0.50
Preprocedural SPP (IQR), mmHg 25 (18e34) 24 (18e40) 0.36
Rutherford class
IV/V/VI 5/19/10 5/22/7 0.69
IQR: interquartile range, BMI: body mass index, ABI: ankle-brachial index, SPP: skin
perfusion pressure.
Table 3
Lesion characteristics.
Variable Cilostazol (þ) Cilostazol () P value
Number of lesions 44 57
Reference vessel diameter (IQR), mm 2.5 (2.0e2.5) 2.5 (2.0e2.5) 0.35
Lesion length (IQR), mm 150 (100e200) 150 (100e200) 0.95
% Diameter stenosis (IQR), % 100 (99e100) 100 (99e100) 0.86
a
216  CLI patients were screened 
Excluded from the analysis owing to:
143 inflow lesion
115 femoropopliteal lesion
28 aortoiliac lesion
73  CLI patients with isolated BTK disease were eligible
From February 2011 to April 2011,
242  consecutive CLI patients were diagnosed
26 received bypass surgery
10 refusal of consent 
63  CLI patients with isolated BTK disease were enrolled for analysis
Figure 1. Study ﬂow chart. BTK: Below the knee.
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success was obtained in 63 patients (100%).
The details of cilostazol treatment are shown in Table 1. In
institutions A and D, cilostazol treatment was performed actively,
while in institution C cilostazol was administered conservatively.
The backgrounds of the patients (Table 2) and lesion characteristics
(Table 3) did not differ signiﬁcantly between the cilostazol and non-
cilostazol groups. Stents and drug-eluting balloons were not used
in the study. During the follow-up period, no patients discontinued
cilostazol or clopidogrel due to side effects.
Outcome measures
Complete follow-up clinical data were obtained from 59
patients (93.7%). In lesion-based analysis, binary restenosis and
reocclusion were found in 73.3% (74/101 lesions) and 32.7% (33/
101), respectively. The cilostazol group had lower rates of angio-
graphic binary restenosis (56.8% [25/44] vs. 86.0% [49/57],
p ¼ 0.015; Fig. 2), reocclusion (20.5% [9/44] vs. 42.1% [24/57],
p ¼ 0.02; Fig. 2), and clinically driven TLR (27.5% [11/44] vs. 49.1%
[28/57], p ¼ 0.01; Fig. 2) compared with the non-cilostazol group.
Cilostazol was effective for avoidance of restenosis (odds ratio [OR]
0.22, 95% conﬁdential interval [CI] 0.08e0.56, p ¼ 0.002; Table 4),
but the other antiplatelet agents did not show this effect (aspirin:
OR 1.83, 95% CI 0.59e5.64, p¼ 0.29; thienopyridine: OR 1.04, 95% CI
0.43e2.50, p ¼ 0.94). There was no signiﬁcant difference in
outcomewith dual or triple antiplatelet therapy compared to single
antiplatelet therapy (OR 0.60, 95% CI 0.21e1.67, p ¼ 0.32).
In limb-based analysis, there were no signiﬁcant differences in
reintervention, complete wound healing and leg salvage between
the cilostazol and non-cilostazol groups (Fig. 3). Surgical conver-
sion was required in one patient in the cilostazol group. In patient-
based analysis, all-cause mortality was 6.3% (4 of 63), including 2Table 1
Distribution of cilostazol treatment in each institution.
Institution Total Cilostazol () (%) Cilostazol (þ) (%)
A 17 5 (29) 12 (71)
B 15 8 (53) 7 (47)
C 10 9 (90) 1 (10)
D 9 2 (22) 7 (78)
E 7 5 (71) 2 (29)
F 3 1 (33) 2 (67)
G 2 1 (50) 1 (50)patients in the cilostazol group due to cardiac death and pneu-
monia, and 2 in the non-cilostazol group due to stroke and sepsis.
No major bleeding complications occurred over the observation
period, and there were no cases of myocardial infarction, non-fatal
stroke or major amputation.
After correcting all endpoints for potential confounders (age,
gender, hyperlipidemia, aspirin and statins), cilostazol was shown
to be effective for avoidance of restenosis (OR 0.16, 95% CI 0.05 to
0.48, adjusted P ¼ 0.001), reocclusion (OR 0.25, 95% CI 0.09 to 0.72,
adjusted P ¼ 0.01) and TLR (OR 0.25, 95% CI 0.09 to 0.63, adjusted
P ¼ 0.004) (Table 4).
Discussion
Our retrospective analysis suggested that treatment with cil-
ostazol reduces restenosis, reocclusion and target lesionCalciﬁed lesion (%) 21 (47.7) 30 (52.6) 0.63
Treated vessel
Anterior tibial 16 (36.4) 25 (43.9) 0.79
Posterior tibial 15 (34.1) 14 (24.6)
Peroneal 7 (15.9) 12 (21.1)
Dorsalis pedis 3 (6.8) 3 (5.3)
Plantar 3 (6.8) 3 (5.3)
TASCb class
A/B/C/D 0/0/2/42 0/0/2/55 0.79
a Calciﬁed lesion deﬁned as obvious densities noted within the apparent vascular
wall in the angiogram.
b TASC: Trans-Atlantic Inter-Society Consensus.
Figure 2. Three-month angiographic outcomes after balloon angioplasty (lesion-based analysis). TLR: target lesion revascularization.
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plasty. These ﬁndings obtained by angiography are important, but
the decision to prescribe cilostazol may have been biased because
the determination of postoperative medication was made by indi-
vidual operators or based on institutional medical regimens.
However, there were no major differences in patient background
and lesion characteristics between the cilostazol and non-cilostazol
groups. The patient background data reﬂect averages between
populations at different institutions at which there was heteroge-
neity of cilostazol use, with two institutions actively administering
cilostazol (>70%), while one institution did not do so (10%)
(Table 1).
After coronary angioplasty, the efﬁcacy of cilostazol for inhibi-
tion of restenosis tended to be higher after balloon angioplasty
compared to that after stent placement.16 Most of the infrapopliteal
lesions in this study were long and were treated by balloon
angioplasty. Therefore, concomitant use of cilostazol is likely to
improve the patency rate. However, there were no differences in
reintervention, wound healing and limb salvage at 3 months
between limbs that did and did not receive cilostazol treatment,
although cilostazol has previously been reported to improve the
limb salvage rate in CLI patients.11 The current results indicate that
a further study is needed to examine whether cilostazol improves
the clinical outcome, in addition to improving restenosis, in CLI
patients.
The effect of cilostazol on restenosis may result from the inhi-
bition of neointimal hyperplasia. Cilostazol reduces restenosis dueTable 4
Primary and secondary outcome measures.
Outcome Cilostazol (þ) N ¼ 44 (%) Cilostazol () N ¼ 57 (%)
Binary restenosis 25 (56.0%) 49 (86.0%)
Re-occlusion 9 (20.5%) 24 (42.1%)
TLR 11 (27.5%) 28 (52.8%)
OR: Odds ratio, CI: conﬁdence interval, TLR: target lesion revascularization. Outcomes wto suppression of migration and proliferation of vascular smooth
muscle cells induced by platelet-derived growth factor.17,18 There
may also be a vasodilation effect induced by the continuous
relaxation of vascular smooth muscle.19 The guidelines for treat-
ment of CLI patients8 also recommend oral administration of
antiplatelet agents to prevent early occlusion by thrombus at the
treatment site, and the occurrence of reocclusion was signiﬁcantly
lower in patients treated with cilostazol in this study (Fig. 2). The
guidelines8 suggest that treatment with an antiplatelet drug is
desirable after revascularization for CLI patients. However, there is
no recommended drug and dosage, and the ideal form of drug
therapy after revascularization in CLI patients has not been
clariﬁed.Limitations
There are several limitations that may have affected our clinical
outcomes. First, we used a retrospective analysis, although this
study was performed as a multicenter prospective study. In addi-
tion, the clinical decision to prescribe cilostazol may have been
biased. Therefore, a randomized clinical trial is needed to verify the
ﬁndings. Second, the observation period was short and the sample
size was underpowered to evaluate clinical outcomes. Therefore,
evaluation of the effect of cilostazol inhibition of restenosis on
improvement of clinical outcome will require a large-scale longer-
term study. Within these limitations, the ﬁndings in this studyUnadjusted or (95% CI) P value Adjusted or (95% CI) P value
0.22 (0.08e0.56) 0.002 0.16 (0.05e0.48) 0.001
0.35 (0.14e0.87) 0.02 0.25 (0.09e0.72) 0.01
0.34 (0.14e0.82) 0.02 0.24 (0.09e0.63) 0.004
ere adjusted by potential covariates: age, gender, hyperlipidemia, aspirin and statin.
Figure 3. Three-month clinical outcomes (limb-based analysis).
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angioplasty.
Conclusion
Our retrospective analysis suggests that cilostazol is associated
with reduced restenosis, reocclusion and clinically driven TLR at 3
months after infrapopliteal angioplasty. However, clinical outcomes
such as limb salvage and mortality for patients treated with and
without cilostazol were similar in this short period. Thus, a further
study is needed to determine if cilostazol improves clinical
outcomes in patients with CLI.
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